quinta-feira, 5 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)

View original at globenewswire.com
GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC) BOCA RATON, FL AND TORONTO, ONTARIO, March 16, 2026 (GLOBE NEWSWIRE) -- GNQ Insilico Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GNQ's integration of Genomics, Artificial Intelligence, and Quantum Computing represents a differentiated approach to addressing significant challenges facing drug discovery and development

    60% confidence

  • Partnering with IB Acquisition Corp. marks a pivotal moment for GNQ as we scale our three comprehensive AI-powered platforms to transform pharmaceutical R&D and healthcare delivery

    60% confidence

  • The Transaction is expected to close in the third quarter of 2026

    60% confidence

  • GNQ is well-positioned to capture meaningful market share

    60% confidence

  • The transaction provides resources and public market visibility to expand commercial partnerships and scale solutions to serve pharmaceutical companies, investors and healthcare providers worldwide

    60% confidence

  • GNQ's Drug Simulation Platform and Digital Twins Platform are slated for release later in 2026

    60% confidence

  • The Transaction is expected to provide approximately $15 million in proceeds to GNQ, including a PIPE of up to $10 million and cash held in IBAC trust account

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,549 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC) — Source | Via News | pt.VIA.NEWS